Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibroblast growth factor receptors (FGFR) Inhibition for Epithelial Solid Tumours: a phase Ib trial of AZD4547 in combination with gemcitabine and cisplatin

Next Previous
X
Search
Trial Profile

Fibroblast growth factor receptors (FGFR) Inhibition for Epithelial Solid Tumours: a phase Ib trial of AZD4547 in combination with gemcitabine and cisplatin

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABSK 091 (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Acronyms FIESTA

    • Most Recent Events

    • 02 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 01 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Interim results (n=19) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top